Qiagen (QGEN) investor relations material

Leadership transition and strategic focus

• New CEO brings extensive industry experience and aims to drive R&D effectiveness and commercial execution, with a focus on simplifying complexity and aligning with company culture.

• Initial 90 days are dedicated to deep listening, learning, and facility visits to assess growth pillars and midterm outlook.

• Strategic review is ongoing, with a clear direction expected within weeks, not months.

Diagnostics and QuantiFERON performance

• Diagnostics segment saw a 2% decline in Q2, with QuantiFERON impacted by reduced immigration testing, removing $35M from revenue.

• U.S. immigration testing revenue is unlikely to return soon, but Middle East volumes may recover over time.

• Adjusted QuantiFERON growth is 5–7%, outpacing the 4–5% market rate, with significant market share and expansion opportunities.

• 60% of customers are now in long-term contracts, and full workflow automation is expected by end of 2027.

• Fastest growth is in immunocompromised patient testing, with diabetes as a future opportunity.

Product innovation and automation

• QIAstat-Dx platform rebounded to 7% growth in Q2, with expectations for double-digit growth in H2, driven by new panels and instrument placements.

• Sample technologies grew 9% in Q2, with three new instruments launched, targeting EUR 20M incremental H2 revenue.

• Automation is a key trend, with most sample prep still manual but conversion accelerating.

• QIAsprint Connect targets 150 placements this year, aiming for significant consumable pull-through and revenue annuities.